Alnylam and Sanofi enter into strategic restructuring
Optimizing development and commercialization of RNAi therapeutics for rare diseases
09-Jan-2018 -
Alnylam Pharmaceuticals, Inc. and Sanofi announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically, Alnylam will obtain global development and ...
amyloidosis
collaborations
drug discovery collaborations
+4